Authors Posts by Joshua Rodriguez

Joshua Rodriguez

3585 POSTS 446 COMMENTS
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

BOS Better Online Solutions BOSC Stock News

B.O.S. Better Online Solutions (USA) (NASDAQ: BOSC)

B.O.S. Better Online Solutions is having an incredibly rough start to the trading session today. In fact, the stock is down well over 10%. However, I have to say that I’m not concerned in the least. In fact, after the big gains we saw yesterday,I was expecting this to happen, just like I’m expecting to see more exponential growth out of the stock. Today, we’ll talk about why yesterday was such a strong day for the stock, why we’re seeing declines today, and what we can expect to see from BOSC moving forward.

Trade smarter and make more money with Tradespoon!

Why BOSC Climbed Yesterday

B.O.S. Better Online Solutions had an incredible day in the market yesterday, and for good reason. Yesterday, before the opening bell, the company reported its earnings for the first fiscal quarter. In the quarter, the company generated a profit of $314,000, which shows incredible growth over the $33,000 we saw in the same quarter a year ago. Revenue was also up substantially. During the first quarter, the company generated revenue in the amount of $8.1 million. This proves a 38% year-over-year growth rate. Following the strong first quarter, BOSC is expecting to see incredibly strong revenue and earnings growth throughout the rest of the year as well.

Why The Stock Is Down Today

As mentioned above, B.O.S. Better Online Solutions is having a rough day in the market today. Currently (11:16), the stock is trading at $3.45 per share after a loss of $0.62 per share, or 15.23%, thus far today. As a result, investors are starting to ask, “Should I be worried about the declines?” In my opinion, the answer is no! In fact, when you look at the reason for today’s declines, it becomes clear that it really isn’t concerning at all.

The reality is that price movement in the market tends to happen through a series of overreactions. Yesterday’s news from BOSC was overwhelmingly positive, and we saw an overwhelmingly strong reaction. However, it can be argued that while the stock deserved growth, the news wasn’t strong enough to support doubling the stock’s value. When these types of things happen, we tend to see a slight correction in the value of the stock in the trading session following the exponential growth. This correction brings the value of the stock down to a more sustainable rate before growth can continue. In my opinion, that’s exactly what we’re seeing from B.O.S. Better Online Solutions today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from BOSC. The reality is that the company has proven its ability to grow. The strong year-over-year growth experienced in the first quarter is expected to continue throughout the year. In the short run, investor excitement is likely to lead to a strong recovery from today’s declines. However, the gains we see in the short run are nothing compared to what I’m expecting to see in the long run. As BOSC continues to produce stronger than expected growth, investor excitement is likely to lead to more dramatic gains in the value of the stock moving forward.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think BOSC is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of Pixabay]

Synergy Pharmaceuticals SGYP Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals has been an incredibly interesting stock to watch as of late and, in my opinion, it has become an incredible opportunity. While there are bears on the stock, there will always be bears on every stock and, in this case, I believe that they are sorely mistaken. The truth is that SGYP is likely to climb dramatically from here. Today, we’ll talk about why…

Trade smarter and make more money with Tradespoon!

Plecanatide Will Be A Big Driver For SGYP

One of the reasons that I have such a bullish view with regard to what we can expect to see from Synergy Pharmaceuticals is plecanatide. The company has been working on the treatment for quite some time now, and I’ve been following them every step of the way. Watching the clinical trials has been very exciting, considering that each one ended with overwhelmingly strong results. In fact, due to these overwhelmingly strong results, the company has submitted a New Drug Application for plecanatide as a treatment for chronic idiopathic constipation. We will see the results of this application by January 2017.

Aside from the current application that is being processed, SGYP is looking to expand the indications associated with plecanatide. In fact, the company is currently in the midst of two pivotal Phase 3 clinical trials surrounding plecanatide as a treatment for irritable bowel syndrome with constipation (IBS-C). This is another indication for which plecanatide is looking overwhelmingly promising. In fact, the CEO of the company, Gary S. Jacob, recently made an announcement with regard to plecanatide as he released the company’s most recent earnings report. Here’s what he had to say:

2016 is off to a strong and promising start for Synergy, highlighted by the U.S. Food and Drug Administration acceptance of our first new drug application for plecanatide in chronic idiopathic constipation… We continued to expand the utility and value of our uroguanylin-based platform technology while significantly strengthening our overall financial position. Moving forward, we believe we are well positioned to successfully execute on key pre-launch activities and will continue to evaluate all strategic options to ensure a successful launch of plecanatide early next year. Meanwhile, we expect top-line data from our two pivotal phase 3 trials with plecanatide in irritable bowel syndrome with constipation in the third quarter and intend to file our second NDA in IBS-C by the end of this year. Our first quarter results demonstrate our profound commitment to optimizing the value of plecanatide and dolcanatide and bringing these important new treatment options to patients suffering from GI diseases.”

Acquisition On The Table?

As you can tell from the above, I’m incredibly excited to see plecanatide hit the market, as I believe that it will be an overwhelmingly profitable treatment for SGYP. However, it’s impossible to ignore another possibility that could send the stock skyrocketing – the possibility of an acquisition. There have been rumors flying around, for some time now, that the company may be considering selling itself in order to better position itself for the commercialization of the treatment. If this is, indeed, the case, it will likely end up being an incredibly high value acquisition, as plecanatide is showing promising signs. So, this is something to keep on the radar.

The Bottom Line

At the end of the day, whether or not Synergy Pharmaceuticals makes the decision to sell itself, the stock is likely to climb. Plecanatide is an incredible treatment, given everything I’ve seen from the clinical trials surrounding it, and dolcanatide looks promising. All in all, the company is on the right track for growth, and that’s exactly what I’m expecting to see from SGYP.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think SGYP is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Pixabay]

0 1719
Do Homework Like A Pro Trader

Mergers and takeovers, record-breaking product sales, surprising economic data – every day profitable trading opportunities appear in the financial markets. Traders and investors use various analysis techniques and strategies to spot them and make a profit.

So why are some traders consistently profitable while others lose money?

One of the most important factors is preparation, in other words, doing your homework.

Trade smarter and make more money with Tradespoon!

Pick A Strategy And Find Opportunities

There are thousands of different investment strategies used in the financial markets today. Some of these, like High-Frequency-Trading, focus on short-term gains earned within nanoseconds, while others are based on long-term price changes driven by macro-economic factors. Some traders like to trade on fundamental or technical data, while others enjoy trading on news.

As a trader, it is important to pick a strategy that suits your needs in terms of asset class, investment horizon, and risk tolerance.

The first step is to learn about the types of strategies that exist and to find one that matches your preferences. The second step is deciding on the types of securities to best execute the strategy with, such as equities, futures, or options. Once you’ve done that, it’s time to search for specific trading opportunities.

The internet provides a plethora of sources. Various sites feature real-time commentary, investment strategies, in-depth analyses, trading ideas, or option trading news.

Get Your Facts Straight

Especially when trading on news, it’s important to get your facts straight and make sure the story you’re trading on is accurate and complete.

When unexpected events happen, some media outlets only report them bit-by-bit, and, if you fail to check various sources, you may be missing an integral part of the story.

There have also been extreme cases, in which reporters fell for rumors or hoaxes that affected the markets. In April 2013, the S&P 500 dropped by almost 1% after a fake tweet alleged that an attack on the White House had happened.

Professional traders usually read several sources or only rely on highly credible ones before trading on news.

Check Whether The Information Is Already Priced In

News travels fast in the financial markets and may be accounted for in a security’s price within seconds or minutes. Other times, it can take several weeks for the stock price to adjust after a big event.

If you read the news in the morning, you may find that the pre-market price of the stock has already moved by several percentage points. Of course, you may still wish to trade if you expect the price to move even further after the market opens. Nonetheless, you should be aware of the price change the news has caused before you open a position, in order to be able to evaluate the amount of potential profit that can still be made.

Review The Security’s Chart

A quick look at the price graph of a stock gives the investor a ton of important information. Professional traders almost always analyze the chart before opening a position in the market.

It can be used to check if news has already been priced in and shows the trader where the stock is currently trading in relation to its price history. You’ll see where the highs and lows were, spot potential resistance levels, and get a good idea of how the stock recently performed.

chart 1

The chart above, for example, clearly shows that Twitter’s share price has been declining steadily, and the stock is currently trading close to its one-year low.

Check The Calendar

Before investing, it is greatly advised to check the calendar for future events related to the security, such as earnings releases or shareholders’ meetings, as well as macro-economic announcements, like central bank interest rates or unemployment statistics. Stock exchanges and various financial media publish economic calendars, e.g. Bloomberg.

Sophisticated traders are always aware of important upcoming events that may affect the price of their investment. Trading algorithms and quantitative strategies often automatically account for such events and announcements and deliberately skip these trading days.

Imagine the following scenario: Unaware that non-farm payrolls will be released the following morning, you take several long positions in the US equity market. The next day, the employment statistics end up below analysts’ expectations and the market drops by 2%. Even though you didn’t intend to trade on labor market data, you unintentionally incorporated that risk.

Know Your Limit

Position sizing is something you’re forced to decide on when you enter into your trade, but risk management is something that some traders only start to think about once their position has turned against them.

Professional and consistently profitable traders don’t just find great market entry points, but also plan their exit right from the start. If the level of risk is defined at the beginning, the decision on when to cut losses becomes automatic, instead of needing to be made in a moment of stress.

Don’t waste your time! Click here to find winning trades in minutes!

There are many ways to manage risk. Stop-loss orders that are placed right after a buy or sell order are a popular and easy way to limit the downside of a trade. Sophisticated investors also research which price-level is appropriate and realistic for a stop-loss order and also allocate an overall stop-loss to their portfolio.

Trading remains risky, but can be highly profitable. If you do your homework well, you’ll limit your risk and will be able to invest more confidently.

[Image Courtesy of Flickr]

ChemoCentryx CCXI Stock News

ChemoCentryx Inc (NASDAQ: CCXI)

ChemoCentryx is having a strong start to the trading day today, and for good reason. The company announced early this morning that it has received PRIME designation from the European Medicines Agency for one of its treatment candidates. Today, we’ll talk about the designation, how the market reacted to the news, and what we can expect to see from CCXI moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

CCXI Receives PRIME Designation From The EMA

As mentioned above, it was announced earlier today that ChemoCentryx received PRIME designation from the EMA for one of its treatment candidates. PRIME, in the term PRIME designation, means PRIority Medicines. The designation was given to the company for CCX168 for the treatment of ANCA-Associated Vasculitis, a condition also known as AAV. The PRIME designation is designed to bring promising innovative medicines to patients more quickly by optimizing and supporting development.

When awarding CCXI with the PRIME designation for CCX168, the EMA noted that nonclinical proof-of-principle has been demonstrated when it comes to two relevant disease models, and the nonclinical safety profile seemed to be reassuring. They also said that the magnitude of effect when treated with CCX168 is promising. In a statement, Thomas J. Schall, Ph.D., President and CEO at CCXI, had the following to offer:

The EMA’s PRIME designation provides further validation of the potential of CCX168 to fulfill a high unmet medical need and change the current treatment paradigm in AAV… The use of steroid-containing standard treatment for AAV is thought to be the single biggest cause of premature death among these patients. Our goal with CCX168 is to eliminate or limit the use of steroids along with their deleterious side effects, while controlling the disease, and possibly, more rapidly. The PRIME designation will allow us to accelerate the regulatory review process, potentially allowing CCX168 to reach the market sooner than previously expected.”

How The Market Reacted To The News

As investors, one of the first things that we learn is that the news moves the market. Any time there is positive news released with regard to a publicly-traded company, we can expect to see gains in the value of the stock associated with that company as a result. In the case of ChemoCentryx, the news that was released today was overwhelmingly positive. As a result, we’re seeing a strong start to the trading session today for the stock. Early in the morning, the value of the stock climbed by more than 4%. However, as the day moves on, the rough day in the market as a whole is driving the stock into the red. Currently (10:07), CCXI is trading at $5.38 per share after a loss of $0.01 per share, or 0.19%, thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from CCXI. The company has done an incredible job with the development of CCX168 thus far, and the new PRIME designation with the EMA will help to further that development, hopefully bringing the treatment to the market relatively soon. This is something that I believe will be overwhelmingly profitable. With a strong pipeline, strong team, and strong management, I’m expecting to see exponential growth from CCXI moving forward.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think CCXI is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Flickr]

Amazon AMZN Stock News

Amazon.com, Inc. (NASDAQ: AMZN)

Ah Amazon. The company is absolutely incredible. However, if you look back to late 2014, you’ll notice a major shift in the overall opinion associated with the stock. While the bulls are out to play at the moment, back then, the bears were controlling the stock in a big way. Today, we’ll talk about why AMZN wasn’t doing too well in late 2014, what caused the overall opinion to shift since, and what we can expect to see from the stock moving forward.

Trade smarter and make more money with Tradespoon!

Why AMZN Wasn’t Doing Well In Late 2014

The Reality is that, by nature, Amazon’s business model took quite a while to reach the profits. While the company grew exponentially quickly, it has been focused on incredibly small margins. So, for the first several years, the company was forced to put every bit of money it was actually making back into growth, never bringing home a profit.

The fact that AMZN wasn’t profitable was already concerning to consumers. However, in late 2015, we started to see big moves from the company. Jeff Bezos went on a spending spree, spending millions-upon-millions of dollars. The goal was simple – build tons of fulfillment centers to improve shipping times. However, with the company still not making it to the profits, investors started to become increasingly concerned. As a result, toward the end of 2014, the stock started to take a dive.

Why Opinions Changed

While investors were overwhelmingly concerned about AMZN in late 2014, when 2015 rolled around, we saw a change in opinion, and it happened fast. On the first earnings report in the year, Amazon finally reported a profit. It wasn’t a huge profit, but the company had finally made it into the green, proving the bears wrong. As a result, we started to see drastic upward movement on the stock, as well as more and more analysts weighing in.

Why Amazon Will Continue To Grow Exponentially

When I first started to follow AMZN, I have to admit, I was concerned about the company. The reality is that the company focused on incredibly small margins to increase sales volume. However, with incredible amounts of overhead costs associated with excessive amounts of fulfillment centers, it simply didn’t seem like it was ever going to be profitable. Sure, in a perfect world, it would work; however, this world is often far from perfect. Nonetheless, the stars aligned just right for AMZN, and based on what I’ve seen recently, I’m expecting to see more gains. Here are the three biggest reasons that I’m expecting to see continued growth out of Amazon:

  • Prime – At first glance, Amazon Prime seems like a losing venture. For $99 per year, consumers get free 2-day shipping on most orders, streaming video, and much more. I know with the amount I order, AMZN is losing on the shipping on my account. However, they don’t care. The truth is that Prime members spend a massive amount of money at Amazon. In fact, the majority of prime members are spending $800 or more per year at AMZN, and I’ll be the first to admit, I spend far more. So, while Prime service costs may end in a loss, the gains the company realizes from sales among prime members makes this service a big hit!
  • AWS – When it comes to cloud computing, Amazon Web Services is still relatively new. Nonetheless, the company has done incredibly well with this service, pushing it to become worth billions in a very short period of time. Even tech industry leaders, like Salesforce.com, are using AWS for their cloud computing needs. This will continue to drive money into AMZN.
  • Fresh – Finally, Amazon is working on a new concept as we speak. The concept is known as Amazon Prime Fresh. With this service, Prime members have the ability to order perishable goods, everything from veggies to milk, meat, cookies, and more, right from home. This is a service that could give Wal-Mart a run for its money. While it’s only available in limited areas at the moment, I believe that this is going to be another big hit from AMZN.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think AMZN is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Flickr]

UniPixel UNXL Stock News

UniPixel Inc (NASDAQ: UNXL)

UniPixel has been hitting the ground running in the new year when it comes to design wins. The company’s XTouch metal mesh touch sensor technology seems to have gained massive attention in the touchscreen market. Today, the company announced that it has landed yet another design win. This marks the 16th design win since the beginning of the year. Today, we’ll talk about the win, how investors are reacting to the news, and what we can expect to see from UNXL moving forward. So, let’s get right to it!

Trade smarter and make more money with Tradespoon!

UNXL Announces 16th Design Win In 2016

As mentioned above, it seems as though UniPixel has created a hit with the XTouch metal mesh touch screen sensor, as the company continues to dominate screen designs in laptops, tablets, and other devices. In fact, earlier today, the company announced its 16th design win for the year 2016. The design the company won is for a 15.6-inch laptop that will be released by one of the company’s existing customers. The new device will be one of many this year that uses the XTouch metal mesh technology, designed by UNXL, to provide superior performance when it comes to stylus and touch sensors. In a statement, Jeff Hawthorne, President and CEO at UNXL, had the following to say with regard to the win:

With this 16th win since the beginning of the year, we make an important move into the broader consumer market. This initial customer program will be similar to the existing commercial program volumes that we have been awarded thus far. However, this underscores the confidence our existing customer is placing in our ability to deliver to a larger segment of the market. Successful execution on this order could lead to higher volume consumer programs in the future with this customer. We are excited with this opportunity.”

How The Market Reacted To The News

As investors, one of the first things that we learn when we get started is that the news moves the market. Any time there is positive news released with regard to a publicly-traded company, we can expect to see gains in the value of the stock associated with that company. Adversely, negative news will generally lead to declines. In this particular case, the news was incredibly positive. However, the market, overall, is taking a bit of a dive today, and, unfortunately, it is dragging UNXL down with it, regardless of the news that was released today. Currently (10:43), the stock is trading at $.175 per share after a loss of $0.02 per share or 1.19% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from UniPixel. Throughout the year, the company has done an incredible job with 16 design wins to date. Not to mention, today’s announcement marks the largest design win of the year! The technologies UNXL has created are lightweight, durable, and, based on the design wins we’ve seen thus far this year, in high demand. These factors, in combination with a great team, incredible management, and a clear plan for growth will likely lead UNXL far higher in the long run.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think UNXL is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of UniPixel]

Intercept Pharmaceuticals ICPT Stock News

Intercept Pharmaceuticals Inc (NASDAQ: ICPT)

Intercept Pharmaceuticals investors have something big to be excited about. The company announced, late on Friday, that the FDA has granted the company approval on one of their liver treatments. Today, we’ll talk about the approval, what we’re seeing in the market as a result, and what we can expect to see from ICPT moving forward. So, let’s get right to it!

Trade smarter and make more money with Tradespoon!

ICPT Announces FDA Approval Of Ocaliva

Intercept Pharmaceuticals has been working on Ocaliva for some time now. The treatment is designed to be used in combination with ursodeoxycholic (UDCA) in order to improve conditions for adults that are currently suffering from primary biliary cholangitis. Ocaliva is an agonist of the farnesoid X receptor, which is a nuclear receptor expressed in the liver and intestine. Ocaliva was approved by the FDA under accelerated approval. The approval was based on a reduction in alkaline phosphate. In a statement, Mark Pruzanski, M.D., President and CEO at ICPT, had the following to offer about the news:

Intercept was founded on the belief that targeting FXR would benefit patients with liver diseases for which there are limited or no treatment options, and Ocaliva’s approval marks the culmination of more than a decade of work… We are very pleased that the FDA has approved Ocaliva for PBC and would like to thank all the patients and investigators around the world who participated in our clinical trials to make this possible.”

This statement was followed up by John Vierling, M.D., F.A.C.P., F.A.A.S.L.D., Professor of Medicine and Surgery at Baylor College of Medicine and Past President of the American Association for the Study of Liver Diseases. Here’s what he had to say:

Ocaliva files an important unmet need for the many patients with PBC who have an inadequate response to or are intolerant of UDCA, which until now has been the only approved treatment… Ocaliva has demonstrated a clinically meaningful improvement in lowering ALP, a liver enzyme and biomarker that is used to track disease progression in patients with PBC. Importantly, Ocaliva maintained durable ALP reductions, which is critical for the treatment of a chronic disease like PBC.”

How The Market Reacted To The News

As investors, one of the first things that we learn is that the news moves the market. In most cases, when positive news is released, we can expect to see gains in the value of the stock associated with the news. Adversely, negative news will generally lead to declines. While the news released with regard to ICPT was overwhelmingly positive, investors seem to be uncertain about the stock at the moment. Surprisingly enough, we are currently seeing declines. Currently (9:55), Intercept Pharmaceuticals stock is trading at $140.90 per share after a loss of $0.87 per share, or 0.61%, thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from ICPT. The reality is that, through Ocaliva, the company has come up with a treatment that is very needed in the medical industry at the moment. The treatment will likely lead to strong profits in the future. However, Ocaliva isn’t the only thing that ICPT has going for it. At the end of the day, the company has a tremendous pipeline as well as an amazing team. This is, generally, a combination that ends in incredible growth!

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think ICPT is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

0 2637
NetApp NTAP Stock News

NetApp Inc. (NASDAQ: NTAP)

NetApp is having an incredibly hard start to the trading session today, and for good reason. The company reported its earnings for the fiscal fourth quarter, missing the mark. Today, we’ll talk about what we saw from earnings, how the market reacted to the news, and what we can expect to see from NTAP moving forward.

Trade smarter and make more money with Tradespoon!

NTAP Reports Q4 Earnings

As mentioned above, NetApp is having a rough start to the day today after reporting its earnings. Here’s what we saw from the report:

  • Earnings Per Share – Unfortunately, neither earnings or revenue proved to be very good for NTAP this quarter. In terms of earnings, the company missed expectations by $0.03 per share. While analysts expected that the company to generate earnings in the amount of $0.58 per share, the actual number came in at $0.55 per share.
  • Revenue – When it comes to revenue, we didn’t see much positive news either. During the fourth quarter, anaysts were expecting that NTAP would generate revenue in the amount of $1.40 billion. However, the company actually reported revenue in the amount of $1.38 billion, shy of analyst expectations.

As you can see from the data above, the news was overwhelmingly negative. As a result of the poor report, Drexel Hamilton made the decision to reiterate the hold rating and $24.50 price target on the stock. In a statement, analyst Brian White had the following to offer:

Last night, NetApp reported a soft 4Q:FY16 performance and offered up a muted 1Q:FY17 outlook that is below our EPS projection. As such, we are slightly trimming our estimates for FY:17 and maintaining our HOLD rating.”

How The Market Reacted To The News

As investors, we’ve learned that the news moves the market. When positive news is released with regard to a publicly-traded company, we can expect to see gains in the value of the company as a result. However, in the case of NTAP, the news that was released was anything but positive. After all, no investor likes to see the company they are investing in missing the mark like this. So naturally, we’re seeing declines on the stock today. Currently (10:13) the stock is trading at $24.74 per share after a loss of $0.78 per share, or 3.08%, thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see from NetApp. First and foremost, in the short run, I’m not expecting to see much by way of positive movement. Between missed earnings in Q4 and the light expectations for Q1, investors aren’t happy at the moment. However, it is important to remember that NTAP has built an incredible company with great products and strong management. In the long run, this company will make it over the hurdle and likely grow!

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think NTAP is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Flickr]

Financial Disconnect

The G-7 global finance meeting failed to yield fresh ideas for spurring global growth.

The Finance ministers of the Group of Seven major economies ended a weekend meeting without agreement on a plan to revive global growth. Most of the G-7 governments favor official action to stimulate demand, but Germany is more conservative. Instead, finance ministers stressed the importance of varying action for each country.

Trade smarter and make more money with Tradespoon!

They have ‘financially engineered’ many life times of public debt, without any success of getting us out of this ‘deflationary spiral’. They had anticipated that these funds provided to the banks would filter down to ‘Main Street’. They were expecting the private sector to spend but they have not.

The global Central Bankers have been struggling to convince businesses to invest in ‘capital spending’ and ‘raise wages’, but this has been a futile effort.

Companies and banks have engaged in ‘record profits’ thanks to ‘easy money’ policies. The major economic problem is the lack of “aggregate demand”. There is no such demand that currently exist globally.

Apparently, the finance leaders of the Group of Seven Industrial Powers have still not learned from their ‘misjudgments’. We are once again doomed to repeat these same mistakes, over and over, again. The solution is not that of ‘monetary stimulus’, but rather of ‘fiscal stimulus’. There needs to be ‘structural reforms’ that should have been implemented, several years ago.

China’s economic contractions have finally caught up to the rest of the world. There was an unprecedented period of ‘rapid growth’ and development from the 1990’s until 2011. It is now experiencing a ‘severe economic slowdown’ which has spread into developing new global financial crisis’ which are presently rippling throughout the world, today!

China brought 800 million of its citizens out of extreme poverty! The government is now shutting down overcapacity in their coal, steel and other heavy industries. Their huge debts and cash flow problems are running throughout their local governments, state owned enterprises and property sectors. There are outbreaks of speculating with their stock markets, and their currency and the corporate bond markets that have now created a global financial ‘systemic risk’ within the banking sector.

It Is Time To WAKE UP!

Currently, global financial markets are extremely ‘distorted’! This spells out danger for both investors and businesses since it is impossible to properly allocate ‘capital efficiently’ within this current economic and financial environment.
The interventions from global Central Bankers and governments have created ‘economic chaos’ by leaving huge debt levels that is near impossible be able to be paid off.

With markets everywhere disrupted by this ‘financial engineering’, do any investors know where to place their money, these days?

It is my belief, that the FED is boxed into a corner. They will not likely raise their short- term interest rates, but they will also be forced to implement QE 4 and/or NIRP in order to hold together the ‘economic house-of-cards’ together!
Recently, the U.S. stock market highs and those of 2008 both occurred under similar economic fundamentals that were rapidly deteriorating. Today, markets are displaying the same exact same pattern that we experienced in 2008.

Unfortunately, this same scenario pattern is right in front of us, again!

Investors have pulled another $3.9 billion from U.S. based stock funds, during the week that ended on May 18th, 2016. This new trend of ‘outflows’ has constantly persisted during most of this year.

Year-to-date outflows from U.S based stock funds, now total $45 billion which rivals the $50 billion in ‘outflows’ during all of 2011. The funds bled out more than $72 billion, in 2008, during the peak of the ‘financial crisis’. This is substantially due to mutual fund investors bailing out of domestic U.S. stocks.

The last ‘crisis’ struck uninformed investors without any warning signs. Consider yourself forewarned now though.

Don’t waste your time! Click here to find winning trades in minutes!

Concluding Thoughts:

In short, Warnings signs are ABUNDANT. And in the next couple articles I post I will paint a very clear picture for you to see for yourself. Stay Tuned!

Get My Reports Delivered Free To Your Inbox: www.TheGoldAndOilGuy.com

Chris Vermeulen

[Image Courtesy of Flickr]

Biodel BIOD Stock news

Biodel Inc (NASDAQ: BIOD)

Biodel is having an incredibly strong start to the trading session today, after making a key announcement early this morning. The company will be merging with a privately-held company. Today, we’ll talk about the merger, how the market is reacting to the news, and what we can expect to see from BIOD moving forward. So, let’s get right to it…

Trade smarter and make more money with Tradespoon!

BIOD Enters Into Merger Agreement

As mentioned above, Biodel is having a strong start to trading today after announcing that it would be merging with another company. The other company involved in the merger is Albireo, a privately-held biotechnology company. The merger will result in a combined company that will be publicly traded. The new company will have the key focus of developing novel bile acid modulators. It is the hope of both companies that this will help to treat orphan pediatric liver diseases, as well as other liver and gastrointestinal diseases and disorders.

One of the first treatments that the combined company will be working on will be the lead candidate at Albireo. BIOD will be involved in progression of the lead candidate, A4250. Initially, the treatment was developed to treat Familial Intrahepatic Cholestasis, also know as PFIC. PFIC is a life threatening, orphan liver disease that is known to affect young children. Currently, the treatment is in the midst of Phase 2 studies.

Under the terms of the merger agreement, Albireo shareholders have already agreed to exchange their shares for newly-issued shares of BIOD common stock. At the end of the merger, Albireo stockholders will be the majority holders of the combined company with 67%, while Biodel stockholders will own approximately 33% of the combined company. The newly formed company will have the name Albireo Pharma, Inc. There are also plans to change the ticker on the stock from BIOD to ALBO. Ron Cooper, the current President and CEO at Albireo, will maintain the role of the CEO of the new, combined company. Here’s what he had to say in a statement:

This transaction with Biodel and concurrent financing is expected to provide Albireo with sufficient captial to advance our lead product candidate, A4250, through an important Phase 2 clinical readout later this year and a subsequent pivotal trial in PFIC… We believe A4250 has potential to greatly benefit patients suffering from a devastating orphan pediatric liver disease with no approved drug treatment options.”

How The Market Reacted To The News

We know that positive news causes positive movements in the market. The news released by BIOD today was overwhelmingly positive. Not to mention, there are few pieces of news that can get investors quite as excited as a merger. So naturally, we’re seeing strong gains in the value of the stock today. Currently (11:46), BIOD is trading at $0.44 per share after a gain of $0.06 per share, or 14.74%, thus far today.

What We Can Expect To See Moving forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Biodel – or the newly formed Albireo Pharma. All in all, the companies fit incredibly well together. With combined financing, the newly formed company will have all the capital it needs to continue the advancement of A4250, which is overwhelmingly promising. All in all, things seem to be looking great.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think BIOD is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of The Blue Diamond Gallery]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7813
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...